Advanced search
Publication Cover
Immunotherapy Volume 2, 2010 - Issue 5
Submit an article Journal homepage
184
Views
0
CrossRef citations to date
0
Altmetric
Review

Immunotherapy in asthma

Richard WarringtonUniversity of Manitoba, GC319, 820 Sherbook Street, Winnipeg, Manitoba, R3A 1R9, Canada.Tel.: +1 204 787 3186 Fax: +1 204 787 [email protected]
Pages 711-725 | Published online: 29 Sep 2010

Bibliography

  • Eder W , EgeMJ, von Mutius E: The asthma epidemic. N. Engl. J. Med.355 , 2226–2235 (2006).
  • Weiss KB , SullivanSD, LyttleCS: Trends in the costs of asthma in the United States, 1985–1994.J. Allergy Clin. Immunol.106 , 493–499 (2000).
  • Lloyd CM , RobinsonDS: Allergen-induced airway remodeling.Eur. Resp. J.29 , 1020–1032 (2007).
  • Slats AM , JanssenK, van Schadewick A et al.: Expression of smooth muscle and extracellular matrix proteins in relation to airway function in asthma. J. Allergy Clin. Immunol.121 , 1196–1202 (2008).
  • Holgate ST , ArshadHS, RobertsGCet al.: A new look at the pathogenesis of asthma.Clin. Sci. (Lond.)118 , 439–450 (2009).
  • Pipet A , BotturiK, PinotD, VervloetD, MagnanA: Allergen-specific immunotherapy in allergic rhinitis and asthma. Mechanisms and proof of efficacy.Respir. Med.103 , 800–812 (2009).
  • Frew AJ : Allergen immunotherapy.J. Allergy Clin. Immunol.125 , S306–S313 (2010).
  • Cox L : Allergen immunotherapy and asthma: efficacy, safety and other considerations.Allergy Asthma Proc.29 , 80–89 (2008).
  • Abramson MJ , PuyRM, WeinerJM: Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials.Am. J. Respir. Crit. Care Med.151 , 969–974 (1995).
  • Abramson MJ : Allergen immunotherapy in asthma.Cochrane Database Syst. Rev.4 , CD001186 (2003).
  • Ross RN , NelsonHS, FinegoldI: Effectiveness of specific immunotherapy in the treatment of asthma: a meta-analysis of prospective, randomized, double-blind, placebo-controlled studies.Clin. Ther.22 , 329–341 (2000).
  • Nelson HS : Multi-allergen immunotherapy for allergic rhinitis and asthma. J. Allergy Clin. Immunol.123 , 763–769 (2009).
  • Halken S , LauS: New visions in specific immunotherapy in children: an iPAC summary and future trends.Pediatr. Allergy Immunol.19(Suppl. 19) , 60–70 (2008).
  • Adkinson NF Jr, Eggleston PA, Eney D et al.: A controlled trial of immunotherapy for asthma in allergic children. N. Engl. J. Med.336 , 324–331 (1997).
  • Hedlin G , WilleS, BrowaldhLet al.: Immunotherapy in children with allergic asthma: effect on bronchial hyperreactivity and pharmacotherapy.J. Allergy Clin. Immunol.103 , 609–614 (1999).
  • Akdis M , AkdisCA: Mechanisms of allergen-specific immunotherapy.J. Allergy Clin. Immunol.119 , 780–791 (2007).
  • Larch M , AkdisCA, ValentaR: Immunological mechanisms of allergen-specific immunotherapy.Nat. Rev. Immunol.6 , 761–771 (2006).
  • Hawrylowicz CM , O‘GarraA: Potential role of IL-10-secreting regulatory T cells in allergy and asthma.Nat. Rev. Immunol.5 , 271–283 (2005).
  • Benjaponpitak S , OroA, MaguireP, MarinkovichV, DeKruyffRH, UmetsuDT: The kinetics of change in cytokine production by CD4 T cells during conventional allergen immunotherapy.J. Allergy Clin. Immunol.103 , 468–475 (1999).
  • Faith A , RichardsDF, VerhoefA, LambJR, LeeTH, HawrylowiczCM: Impaired secretion of interleukin-4 and interleukin-13 by allergen-specific T cells correlates with defective nuclear expression of NF-AT2 and Jun B: relevance to immunotherapy.Clin. Exp. Allergy3 , 1209–1215 (2003).
  • Kim HB , JinHS, LeeSYet al.: The effect of rush immunotherapy with house dust mite in the production of IL-5 and IFN-γ from the peripheral blood T cells of asthmatic children.J. Korean Med. Sci.24 , 392–397 (2009).
  • Chen ZG , LiM, ChenYFet al.: Effects of dermatophagoides pteronyssinus allergen-specific immunotherapy on the serum interleukin-13 and pulmonary functions in asthmatic children.Chin. Med. J. (Engl.)122 , 1157–1161 (2009).
  • Till S , WalkerS, DickasonRet al.: IL-5 production by allergen-stimulated T cells following grass pollen immunotherapy for seasonal allergic rhinitis.Clin. Exp. Immunol.110 , 114–121 (1997).
  • Wachholz PA , Nouri-AriaKT, WilsonDRet al.: Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios.Immunology105 , 56–62 (2002).
  • Francis JN , TillSJ, DurhamSR: Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy.J. Allergy Clin. Immunol.111 , 1255–1261 (2003).
  • Durham SR , YingS, VarneyVAet al.: Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-≫.J. Allergy Clin. Immunol.97 , 1356–1365 (1996).
  • Wilson DR , Nouri-AriaKT, WalkerSMet al.: Grass pollen immunotherapy: symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season.J. Allergy Clin. Immunol.107 , 971–976 (2001).
  • Nouri-Aria KT , PiletteC, JacobsonMR, WatanabeH, DurhamSR: IL-9 and c-Kit+mast cells in allergic rhinitis during seasonal allergen exposure: effect of immunotherapy.J. Allergy Clin. Immunol.116 , 73–79 (2005).
  • Plewako H , WosinskaK, ArvidssonMet al.: Basophil interleukin 4 and interleukin 13 production is suppressed during the early phase of rush immunotherapy.Int. Arch. Allergy Immunol.141 , 346–353 (2006).
  • Plewako H , WosinskaK, ArvidssonM, BjorkanderJ, HakanssonL, RakS: Production of interleukin-12 by monocytes and interferon-γ by natural killer cells in allergic patients during rush immunotherapy.Ann. Allergy Asthma Immunol.97 , 464–468 (2006).
  • James LK , DurhamSR: Update on mechanisms of allergen injection immunotherapy.Clin. Exp. Allergy38 , 1074–1088 (2008).
  • Francis J , JamesL, ParaskevopoulosGet al.: Grass pollen immunotherapy: Il-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity.J. Allergy Clin. Immunol.121 , 1120–1125 (2008).
  • Calamita Z , SaconatoH, PeláAB, AtallahAN: Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method.Allergy61 , 1162–1172 (2006).
  • Compalati E , PassalacquaG, BoniniM, CanonicaGW: The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis.Allergy64 , 1570–1579 (2009).
  • Marseglia GL , IncorvaiaC, La Rosa M, Frati F, Marcucci F: Sublingual immunotherapy in children: facts and needs. Ital. J. Pediatr.35 , 31 (2009).
  • Larenas-Linnermann DE , CoxLS: Sublingual immunotherapy for asthma. Need for high quality meta-analyses to prove the concept.Allergy62 , 704–705 (2007).
  • Pajno GB , PassalacquaG, VitaDet al.: Sublingual immunotherapy abrogates seasonal bronchial hyperrresponsiveness in children with Parietaria-induced respiratory allergy; a randomized controlled trial.Allergy59 , 883–887 (2004).
  • Nieto A , MazonA, PamiesR, BrunoL, NavarroM, MontanesA: Sublingual immunotherapy for allergic respiratory diseases: an evaluation of meta-analyses.J. Allergy Clin. Immunol.124 , 157–161 (2009).
  • Kuo CH , WangWL, ChuYT, LeeMS, HungCH: Sublingual immunotherapy in children: an updated review.Pediatr. Neonatol.50 , 44–49 (2009).
  • Larenas-Linnemann D : Certainties and doubts about sublingual and oral immunotherapy in children.Curr. Opin. Allergy Clin. Immunol.9 , 558–567 (2009).
  • Bohle B , KinaciyanT, GerstmayrM, RadakovicsA, Jahn-SchmidB, EbnerC: Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation.J. Allergy Clin. Immunol.120 , 707–713 (2007).
  • Moingeon P , BatardT, FadelR, FratiF, SieberJ, Van Overtvelt L: Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy61 , 151–165 (2006).
  • Tseng SH , FuLS, NongBR, WengJD, ShyurSD: Changes in serum specific IgG4 and IgG4/IgE ratio in mite-sensitized Taiwanese children with allergic rhinitis receiving short-term sublingual-swallow immunotherapy: a multicenter, randomized, placebo-controlled trial.Asian Pac. J. Allergy Immunol.26 , 105–112 (2008).
  • Allam JP , NovakN, FuchsCet al.: Characterization of dendritic cells from human oral mucosa: a new Langerhans cell type with high constitutive FcεRI expression.J. Allergy Clin. Immunol.112 , 141–148 (2003).
  • Allam JP , NiederhagenB, BüchelerM, et al.: Comparative analysis of nasal and oral mucosa dendritic cells. Allergy61 , 166–172 (2006).
  • Scadding G , DurhamS: Mechanisms of sublingual immunotherapy.J. Asthma46 , 322–334 (2009).
  • Maestrelli P , ZanollaL, PozzanM, Fabbri LM: Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite. J. Allergy Clin. Immunol.113 , 643–649 (2004).
  • Jacobsen L , NiggemannB, DreborgSet al.; for the PAT investigator group: Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy62 , 943–948 (2007).
  • Niggemann B , JacobsenL, DreborgSet al.: Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children.Allergy61 , 855–859 (2006).
  • Möller C , DreborgS, FerdousiHAet al.: Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study).J. Allergy Clin. Immunol.109 , 251–256 (2002).
  • Quirino T , IemoliE, SicilianiE: Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study.Clin. Exp. Allergy26 , 1253–1261 (1996).
  • Mungan D , MisirligilZ, GürbüzL: Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma – a placebo controlled study.Ann. Allergy Asthma Immunol.82 , 485–490 (1999).
  • Khinchi MS , PoulsenLK, CaratF, AndréC, HansenAB, MallingHJ: Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study.Allergy5945–5953 (2004).
  • Mauro M , RusselloM, IncorvaiaC, GazzolaGH, Di Cara G, Frati F: Comparison of efficacy, safety and immunologic effects of subcutaneous and sublingual immunotherapy in birch pollinosis: a randomized study. Eur. Ann. Allergy Clin. Immunol.39, 119–122 (2007).
  • Eifan AO , AkkocT, YildizAet al.: Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial.Clin. Exp. Allergy40 , 922–932 (2010).
  • Larenas-Linnermann D : Subcutaneous and sublingual immunotherapy in children: complete update on controversies, dosing and efficacy.Curr Allergy Asthma Rep.8 , 465–474 (2008).
  • Giovane A , BardareM, PassalacquaG: A three year double blind placebo controlled study with oral immunotherapy to pediatric patients.Clin. Exp. Allergy24 , 53–59 (1994).
  • Durham SR , EmmingerW, KappAet al.: Long term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy.J. Allergy Clin. Immunol.125 , 131–138 (2010).
  • Moller C , DreborgS, LannerA, BjorkstenB: Oral immunotherapy of children with rhinoconjuctivitis due to birch pollen allergy.Allergy41 , 271–277 (1986).
  • Mosbech H , DrebergS, MadsennF: High dose grass pollen tablets used for hyposensitization in hay fever patients. A 1 year double blind placebo controlled study.Allergy42 , 451–455 (1987).
  • Canonica GW , PassalacquaG: Noninjection routes for immunotherapy.J. Allergy Clin. Immunol.111 , 437–448 (2003).
  • Tari MG , MancinoM, MontiG: Immunotherapy by inhalation of allergen in powder in house dust allergic asthma: a double blind study.J. Invest. Allergol. Clin. Immunol.2 , 59–67 (1992).
  • Schumacher MJ , PainMC: Intranasal immunotherapy with polymerized grass pollen allergens.Allergy37 , 241–248 (1982).
  • Kussebi F , KaramlooF, RhynerCet al.: A major allergen gene-fusion protein for potential usage in allergen-specific immunotherapy.J. Allergy Clin. Immunol.115 , 323–329 (2005).
  • Karamloo F , Schmid-GrendelmeierP, KussebiFet al.: Prevention of allergy by a recombinant multi-allergen vaccine with reduced IgE binding and preserved T cell epitopes.Eur. J. Immunol.35 , 3268–3276 (2005).
  • Chapman MD , SmithAM, VailesLD, ArrudaLK, DhanarajV, PomesA: Recombinant allergens for diagnosis and therapy of allergic diseases.J. Allergy Clin. Immunol.106 , 409–418 (2000).
  • Jutel M , JaegerL, SuckR, MeyerH, FiebigH, CromwellO: Allergen-specific immunotherapy with recombinant grassJ. Allergy Clin. Immunol.116 , 608–613 (2005).
  • Niederberger V , HorakF, NiederbergerV et al.: Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc. Natl Acad. Sci. USA101 , 14677–14682 (2004).
  • HayGlass KT , StefuraBP: Anti-interferon-γ treatment blocks the ability of glutaraldehyde-polymerized allergens to inhibit specific IgE responses.J. Exp. Med.173 , 279–285 (1991).
  • Secrist H , DeKruyffRH, UmetsuDT: Interleukin 4 production by CD4+ cells from allergic individuals is modulated by allergen concentration and antigen-presenting cell type.J. Exp. Med.181 , 1081–1090 (1995).
  • Malet A , LluchM, ValeroAL, CasanovasM: Clinical and immunological effects of immunotherapy with glutaraldehyde modified house dust mite extract.Allergol. Immunopathol. (Madr.)22 , 226–232 (1994).
  • Ohman S , BjorkanderJ, DreborgS, LannerA, MallingHJ, WeekeB: A preliminary study of immunotherapy with a monomethoxy polyethylene glycol modified honey bee venom preparation.Allergy41 , 81–88 (1986).
  • Pollock KG , ConacherM, WeiXQ, AlexanderJ, BrewerJM: Interleukin 18 plays a role in both the alum-induced T helper 2 response and the T helper 1 response induced by alum-adsorbed interleukin-12.Immunology108 , 137–143 (2003).
  • Henriksen-Lacey M , ChristensenD, BramwellVWet al.: Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response.J. Con. Rel.145(2) , 102–108 (2010).
  • Arora N , GangalSV: Efficacy of liposome entrapped allergen in regulation of IgE response in mice.Clin. Exp. Allergy22 , 35–42 (1992).
  • Gangal SV , AroraN, ChughL, SehraS, SinghB, MalikBK: Immunomodulation and immunotherapy using liposome entrapped allergens.Arb. Paul Ehrlich Inst. Bundesamt. Sera. Impfstoffe Frankf. AM93 , 267–273 (1999).
  • Sehra S , ChugL, GangalSV: Polarized Th1 responses by liposome entrapped allergen and its potential in immunotherapy of allergic disorders.Clin. Exp. Allergy28 , 1530–1537 (1998).
  • Cevc G , GebauerD, StieberJ, SchätzleinA, BlumeG: Ultraflexible vesicles, Transfersomes, have an extremely low pore penetration resistance and transport therapeutic amounts of insulin across the intact mammalian skin.Biochim. Biophys. Acta19(1368) , 201–215. (1998).
  • Von Garnier C , AstoriM, KettnerAet al.: Allergen-derived long peptide immunotherapy down-regulates specific IgE response and protects from anaphylaxis.Eur. J. Immunol.30 , 1638–1645 (2000).
  • Larche M : Update on the current status of peptide immunotherapy.J. Allergy Clin. Immunol.119 , 906–909 (2007).
  • Campbell JD , BucklandKF, McMillanSJet al.: Peptide immunotherapy in allergic asthma generates IL-10 dependent immunological tolerance associated with linked epitope suppression.J. Exp. Med.206 , 1535–1547 (2009).
  • Pene J , DesrochesA, ParadisLet al.: Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats.J. Allergy Clin. Immunol.102 , 571–578 (1998).
  • Alexander C , TarziM, LarcheM, KayAB: The effect of Fel d 1-derived T cell peptides on upper and lower airway outcome measurements in cat-allergic subjects.Allergy60 , 1269–1274 (2005).
  • Oldfield W , LarcheM, KayA: Effect of T cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomized controlled trial.Lancet360 , 47–53 (2002).
  • Verhoef A , AlexanderC, KayAB, LarcheM: T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity.PLoS Med.2 , E78 (2005).
  • Hartl A , HochreiterR, StepanoskaT, FerreiraF, ThalhamerJ: Characterization of the protective and therapeutic efficiency of a DNA vaccine encoding the major birch pollen allergen Bet v la.Allergy59 , 65–73 (2004).
  • Jarman ER , LambJR: Reversal of established CD4+ type 2 T helper-mediated allergic airway inflammation and eosinophilia by therapeutic treatment with DNA vaccines limits progression towards chronic inflammation and remodeling.Immunology112 , 631–642 (2004).
  • Horner AA , RedeckeV, RazE: Toll-like receptor ligands: hygiene, atopy and therapeutic implications.Curr. Opin. Allergy Clin. Immunol.4 , 555–561 (2004).
  • Krieg AM : Therapeutic potential of Toll-like receptor 9 activation.Nat. Rev. Drug Discov.5 , 471–484 (2006).
  • Klinman DM , YiAK, BeaucageSL, ConoverJ, KriegAM: CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon-γ.Proc. Natl Acad. Sci. USA93 , 2879–2883 (1996).
  • Roman M , Martin-OrozcoE, GoodmanJSet al.: Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants.Nat. Med.3 , 849–854 (1997).
  • Shirota H , SanoK, KikuchiT, TamuraG, ShiratoK: Regulation of murine airway eosinophilia and Th2 cells by antigen-conjugated CpG oligode-oxynucleotides as a novel antigen-specific immunomodulator.J. Immunol.164 , 5575–5582 (2000).
  • Santeliz JV , Van Nest G, Traquina P, Larsen E, Wills-Karp M: Amb a 1-linked CpG oligodeoxynucleotides reverse established airway hyperresponsiveness in a murine model of asthma. J. Allergy Clin. Immunol.109 , 455–462 (2002).
  • Tighe H , TakabayashiK, SchwartzDet al.: Conjugation of immunostimulatory DNA to the short ragweed allergen Amb a 1 enhances its immunogenicity and reduces its allergenicity.J. Allergy Clin. Immunol.106 , 124–134 (2000).
  • Horner AA , TakabayashiK, BeckLet al.: Optimized conjugation ratios lead to allergen immunostimulatory oligodeoxynucleotide conjugates with retained immunogenicity and minimal anaphylactogenicity.J. Allergy Clin. Immunol.110 , 413–420 (2002).
  • Marshall JD , AbtahiS, EidenJJet al.: Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokines expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweedAllergy J. Allergy Clin. Immunol.108 , 191–197 (2001).
  • Creticos PS , LichtensteinLM: Progress in the development of new methods of immunotherapy: potential application of immunostimulatory DNA-conjugated to allergens for treatment of allergic respiratory conditions.Arb. Paul Ehrlich Inst. Bundesamt. Sera. Impfstoffe Frankf. AM.94 , 304–312 (2003).
  • Creticos PS , ChenYH, SchroederJT: New approaches in immunotherapy: allergen vaccination with immunostimulatory DNA.Immunol. Allergy Clin. North Am.24 , 569–581 (2004).
  • Gauvreau GM , HesselEM, BouletLP, CoffmanRL, O‘ByrnePM: Immunostimulatory sequences regulate interferon-inducible genes but not allergic airwave responses.Am. J. Respir. Crit. Care Med.174 , 15–20 (2006).
  • Revets H , PynaertG: Lipoprotein I, a TLR2/4 ligand modulates Th2-driven allergic immune responses.J. Immunol.174 , 1097–1103 (2005).
  • Taylor RC , RichmondP, UphamJW: Toll-like receptor 2 ligands inhibit TH2 responses.J. Allergy Clin. Immunol.117 , 1148–1154 (2006).
  • Takeda K , AkiraS: Toll-like receptors in innate immunity.Int. Immunol.17 , 1–14. (2005).
  • Klinman DM : Immunotherapeutic uses of CpG oligodeoxynucleotides.Nat. Rev. Immunol.4(4) , 249–258 (2004).
  • Antoniu SA : Daclizumab a novel corticosteroid-sparing therapy for asthma?Expert Opin. Investig. Drugs18 , 369–371 (2009).
  • Busse WW , IsraelE, NelsonHSet al.: Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial.Am. J. Respir. Crit. Care Med.178 , 1002–1008 (2008).
  • Kips JC , TournovKG, PauwelsRA: New anti-asthma therapies: suppression of the effect of interleukin (IL)-4 and IL-5.Eur. Respir. J.17 , 499–506 (2001).
  • Borish LC , NelsonHS, LanzMJet al.: Interleukin-4 receptor in moderate atopic asthma. A Phase I/II randomized, placebo-controlled trial.Am. J. Respir. Crit. Care Med.160 , 1816–1823 (1999).
  • Borish LC , NelsonHS, CorrenJet al.: Efficacy of soluble IL-4 receptor for the treatment of adults with asthma.J. Allergy Clin. Immunol.107 , 963–970 (2001).
  • Steinke JW : Anti-interleukin-4 therapy.Immunol. Allergy Clin. North Am.24 , 599–614 (2004).
  • Burmeister Getz E , FisherDM, FullerR: Human pharmacokinetics/pharmacodynamics of an interleukin-4 and interleukin-13 dual antagonist in asthma.J. Clin. Pharmacol.49 , 1025–1036 (2009).
  • Cheng G , ArimaM, HondaKet al.: Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model.Am. J. Respir. Crit. Care Med.166 , 409–416 (2002).
  • White B , LeonF, WhiteW, RobbieG: Two first-in-human, open-label, Phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers.Clin. Ther.31 , 728–740 (2009).
  • Bryan SA , O‘ConnorBJ, MattiS, et al.: Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet356 , 2149–2153 (2000).
  • Kim TS , DeKruyffRH, RupperR, MaeckerHT, LevyS, UmetsuDT: An ova-IL-12 fusion protein is more effective than OVA plus rIL-12 in inducing a Th1-dominated immune response and inhibiting antigen-specific IgE production.J. Immunol.158 , 4137–4144 (1997).
  • Leckie M , BrinkeA: Effects of an interleukin-5 blocking monoclonal antibody on eosinophils airway hyperresponsiveness, and the late asthmatic response.Lancet356 , 2144–2148 (2000).
  • Flood-Page P , SwensonC, FaifermanIet al.: International Mepolizumab Study Group. A study to evaluate the safety and efficacy of mepolizumab in patients with moderate persistent asthma.Am. J. Respir. Crit. Care Med.176 , 1062–1071 (2007).
  • Flood-Page P , Menzies-GowA, PhippsSet al.: Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics.J. Clin. Invest.112 , 1029–1036 (2003).
  • Bradding P , GreenRH: Subclinical phenotypes of asthma.Curr. Opin. Allergy Clin. Immunol.10 , 54–59 (2010).
  • Broide DH : Immunologic and inflammatory mechanisms that drive asthma progression to remodeling.J. Allergy Clin. Immunol.121 , 560–570 (2008).
  • Louten J , BonifaceK, de Waal Malefyt R: Development and function of Th17 cells in health and disease. J. Allergy Clin. Immunol.123 , 1004–1011 (2009).
  • Fouser LA , WrightJF, Dunussi-JoannopoulosK, CollinsM: Th17 cytokines and their emerging roles in inflammation and autoimmunity.Immunol. Rev.226 , 87–102 (2008).
  • Kawaguchi M , KokubuF, FujitaJ, HuangSK, HizawaN: Role of interleukin-17F in asthma.Inflamm. Allergy Drug Targets8 , 383–389 (2009).
  • He R , KimHY, YoonJet al.: Exaggerated IL-17 response to epicutaneous sensitization mediates airway inflammation in the absence of IL-4 and IL-13.J. Allergy Clin. Immunol.124 , 761–770 (2009).
  • Pollock KG , ConacherM, WeiXQ, AlexanderJ, BrewerJM: Interleukin-18 plays a role in both the alum-induced T helper 2 response and the T helper 1 response induced by alum-adsorbed interleukin-12.Immunology108 , 137–143 (2003).
  • Yamagata S , TomitaK, SatoR, NiwaA, HigashinoH, TohdaY: Interleukin-18-deficient mice exhibit diminished chronic inflammation and airway remodelling in ovalbumin-induced asthma model.Clin. Exp. Immunol.154 , 295–304 (2008).
  • Walter DM , WongCP, DeKruyffRH, BerryGJ, LevyS, UmetsuDT: IL-18 gene transfer by adenovirus prevents the development of and reverses established allergen induced airway hyper reactivity.J. Immunol.166 , 6392–6398 (2001).
  • Maecker HT , HansenG, WalterDM, DeKruyffRH, LevyS, UmetsuDT: Vaccination with allergen-IL-18 fusion DNA protects against, and reverses established, airway hyperreactivity in a murine asthma model.J. Immunol.166 , 959–965 (2001).
  • Harada M , ObaraK, HirotaTet al.: A functional polymorphism in IL-18 is associated with severity of bronchial asthma.Am. J. Respir. Crit. Care Med.180 , 1048–1055 (2009).
  • Rickel EA , SiegelLA, YoonBRet al.: Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities.J. Immunol.181 , 4299–4310 (2008).
  • Ballantyne SJ , BarlowJL, JolinHEet al.: Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma.J. Allergy Clin. Immunol.120 , 1324–1331 (2007).
  • Choi IW , Sun-Kim, Kim YS, Ko HM, et al.: TNF-α induces the late-phase airway hyperresponsiveness and airway inflammation through cytosolic phospholipase A(2) activation. J. Allergy Clin. Immunol.116 , 537–543 (2005).
  • Hutchison S , Choo-KangBS, BundickRV: Tumour necrosis factor-α blockade suppresses murine allergic airways inflammation.Clin. Exp. Immunol.151 , 114–122 (2008).
  • Kim YS , KoHM, KangNIet al.: Mast cells play a key role in the development of late airway hyperresponsiveness through TNF-α in a murine model of asthma.Eur. J. Immunol.37 , 1107–1115 (2007).
  • Thomas PS , YatesDH, BarnesPJ: Tumor necrosis factor a increases airway responsiveness and sputum neutrophilia in normal human subjects.Am. J. Respir. Crit. Care Med.152 , 76–80 (1995).
  • Thomas PS , HeywoodG: Effects of inhaled tumour necrosis factor-α in subjects with mild asthma.Thorax57 , 774–778 (2002).
  • Paulsson Y , AustgulenR, HofsliE, HeldinCH, WestermarkB, Nissen-MeyerJ: Tumor necrosis factor-induced expression of platelet-derived growth factor A-chain messenger RNA in fibroblasts.Exp. Cell Res.180 , 490–496 (1989).
  • Palombella VJ , MendelsohnJ, VilcekJ: Mitogenic action of tumor necrosis factor in human fibroblasts: interaction with epidermal growth factor and platelet-derived growth factor.J. Cell. Physiol.135 , 23–31 (1988).
  • Amrani Y , ChenH, PanettieriRA Jr: Activation of tumor necrosis factor receptor 1 in airway smooth muscle: a potential pathway that modulates bronchial hyper-responsiveness in asthma? Respir. Res.1 , 49–53 (2000).
  • Berry M , BrightlingC, AmraniY: Targeting TNF-α: a novel therapeutic approach for asthma.J. Allergy Clin. Immunol.121 , 5–10 (2008).
  • Howarth PH , BabuKS, ArshadHSet al.: Tumour necrosis factor (TNFα) as a novel therapeutic target in symptomatic corticosteroid dependent asthma.Thorax60 , 1012–1018 (2005).
  • Antoniu SA , MihaltanF, UlmeanuR: Anti-TNF-α therapies in chronic obstructive pulmonary diseases.Expert Opin. Investig. Drugs17 , 1203–1211 (2008).
  • Gjurow D , GrzelewskiT, SobocinskaA, StelmachI: Tumour necrosis factor inhibitors in pediatric asthma.Recent Pat. Inflamm. Allergy Drug Discov.3(2) , 143–148 (2009).
  • Wenzel SE , BarnesPJ, BleeckerERet al.: A randomized double-blind placebo controlled study of tumor necrosis factor-α blockade in severe persistent asthma.Am. J. Respir. Crit. Care Med.179 , 549–558 (2009).
  • Prussin C , GriffithDT, BoeselKM, LinH, FosterB, CasaleTB: Omalizumab treatment downregulates dendritic cell FcεRI expression.J. Allergy Clin. Immunol.112 , 1147–1154 (2003).
  • Kopp MV , BrauburgerJ, RiedingerFet al.: The effect of anti-IgE treatment on in vitro leukotriene release in children with seasonal allergic rhinitis.J. Allergy Clin. Immunol.110 , 728–735 (2002).
  • Djukanovi R , WilsonSJ, KraftMet al.: Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.Am. J. Respir. Crit. Care Med.170 , 583–593 (2004).
  • Walker S , MonteilM, PhelanK, LassersonTJ, WaltersEH: Anti-IgE for chronic asthma in adults and children.Cochrane Database Syst. Rev.2 , CD003559 (2006).
  • Casale TB , BusseWW, KlineJNet al.: Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis.J. Allergy Clin. Immunol.117 , 134–140 (2006).
  • Cox LS : How safe are the biologicals in treating asthma and rhinitis?Allergy Asthma Clin. Immunol.22(5) , 4 (2009).
  • Gringeri A , MusiccoM, HermansPet al.: Active anti-interferon-α immunization: a European–Israeli, randomized, double-blind, placebo-controlled clinical trial in 242 HIV-1-infected patients (the EURIS study).J. Acquir. Immune Defic. Syndr. Hum. Retrovirol.20 , 358–370 (1999).
  • Gonzalez G , CrombetT, CatalaMet al.: A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial.Ann. Oncol.9 , 431–435 (1998).
  • Rohn TA , JenningsGT, HernandezMet al.: Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis.Eur. J. Immunol.36 , 2857–2867 (2006).
  • Uyttenhove C , ArendseB, StroobantV, BrombacherF, Van Snick J: Development of an anti-IL-12 p40 auto-vaccine: protection in experimental autoimmune encephalomyelitis at the expense of increased sensitivity to infection. Eur. J. Immunol.34 , 3572–3581 (2004).
  • Uyttenhove C , Van Snick J: Development of an anti-IL-17A auto-vaccine that prevents experimental auto-immune encephalomyelitis. Eur. J. Immunol.36 , 2868–2874 (2006).
  • Ma Y , HayglassKT, BeckerABet al.: Novel cytokine peptide-based vaccines: an interleukin-4 vaccine suppresses airway allergic responses in mice.Allergy62 , 675–682 (2007).
  • Zuany-Amorim C , ManliusC, DalumIet al.: Induction of TNF-α autoantibody production by AutoVac TNF106: a novel therapeutic approach for the treatment of allergic diseases.Int. Arch. Allergy Immunol.133 , 154–163 (2004).
  • Ma Y , HayGlassKT, BeckerABet al.: Novel recombinant interleukin-13 peptide-based vaccine reduces airway allergic inflammatory responses in mice.Am. J. Respir. Crit. Care Med.176 , 439–445 (2007).
  • Bischoff SC : Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data.Nat. Rev. Immunol.7(2) , 93–104 (2007).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.